Table of Content

1 Study Coverage
1.1 Short-acting Recombinant Human Erythropoietin Product Introduction
1.2 Market by Type
1.2.1 Global Short-acting Recombinant Human Erythropoietin Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Epoetin-alfa
1.2.3 Epoetin-beta
1.2.4 Darbepoetin-alfa
1.2.5 Others
1.3 Market by Application
1.3.1 Global Short-acting Recombinant Human Erythropoietin Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Anemia
1.3.3 Kidney Disorders
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Short-acting Recombinant Human Erythropoietin Sales Estimates and Forecasts 2018-2029
2.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Region
2.2.1 Global Short-acting Recombinant Human Erythropoietin Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024)
2.2.3 Global Short-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029)
2.2.4 Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2029)
2.3 Global Short-acting Recombinant Human Erythropoietin Sales Estimates and Forecasts 2018-2029
2.4 Global Short-acting Recombinant Human Erythropoietin Sales by Region
2.4.1 Global Short-acting Recombinant Human Erythropoietin Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024)
2.4.3 Global Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029)
2.4.4 Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Short-acting Recombinant Human Erythropoietin Sales by Manufacturers
3.1.1 Global Short-acting Recombinant Human Erythropoietin Sales by Manufacturers (2018-2024)
3.1.2 Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Short-acting Recombinant Human Erythropoietin in 2022
3.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Manufacturers
3.2.1 Global Short-acting Recombinant Human Erythropoietin Revenue by Manufacturers (2018-2024)
3.2.2 Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Short-acting Recombinant Human Erythropoietin Revenue in 2022
3.3 Global Key Players of Short-acting Recombinant Human Erythropoietin, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Short-acting Recombinant Human Erythropoietin Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Short-acting Recombinant Human Erythropoietin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Product Offered and Application
3.8 Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Short-acting Recombinant Human Erythropoietin Sales by Type
4.1.1 Global Short-acting Recombinant Human Erythropoietin Historical Sales by Type (2018-2024)
4.1.2 Global Short-acting Recombinant Human Erythropoietin Forecasted Sales by Type (2024-2029)
4.1.3 Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
4.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Type
4.2.1 Global Short-acting Recombinant Human Erythropoietin Historical Revenue by Type (2018-2024)
4.2.2 Global Short-acting Recombinant Human Erythropoietin Forecasted Revenue by Type (2024-2029)
4.2.3 Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
4.3 Global Short-acting Recombinant Human Erythropoietin Price by Type
4.3.1 Global Short-acting Recombinant Human Erythropoietin Price by Type (2018-2024)
4.3.2 Global Short-acting Recombinant Human Erythropoietin Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Short-acting Recombinant Human Erythropoietin Sales by Application
5.1.1 Global Short-acting Recombinant Human Erythropoietin Historical Sales by Application (2018-2024)
5.1.2 Global Short-acting Recombinant Human Erythropoietin Forecasted Sales by Application (2024-2029)
5.1.3 Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
5.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Application
5.2.1 Global Short-acting Recombinant Human Erythropoietin Historical Revenue by Application (2018-2024)
5.2.2 Global Short-acting Recombinant Human Erythropoietin Forecasted Revenue by Application (2024-2029)
5.2.3 Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
5.3 Global Short-acting Recombinant Human Erythropoietin Price by Application
5.3.1 Global Short-acting Recombinant Human Erythropoietin Price by Application (2018-2024)
5.3.2 Global Short-acting Recombinant Human Erythropoietin Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Short-acting Recombinant Human Erythropoietin Market Size by Type
6.1.1 US & Canada Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
6.1.2 US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
6.2 US & Canada Short-acting Recombinant Human Erythropoietin Market Size by Application
6.2.1 US & Canada Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
6.2.2 US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
6.3 US & Canada Short-acting Recombinant Human Erythropoietin Market Size by Country
6.3.1 US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
6.3.3 US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Short-acting Recombinant Human Erythropoietin Market Size by Type
7.1.1 Europe Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
7.1.2 Europe Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
7.2 Europe Short-acting Recombinant Human Erythropoietin Market Size by Application
7.2.1 Europe Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
7.2.2 Europe Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
7.3 Europe Short-acting Recombinant Human Erythropoietin Market Size by Country
7.3.1 Europe Short-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
7.3.3 Europe Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Short-acting Recombinant Human Erythropoietin Market Size
8.1.1 China Short-acting Recombinant Human Erythropoietin Sales (2018-2029)
8.1.2 China Short-acting Recombinant Human Erythropoietin Revenue (2018-2029)
8.2 China Short-acting Recombinant Human Erythropoietin Market Size by Application
8.2.1 China Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
8.2.2 China Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Short-acting Recombinant Human Erythropoietin Market Size by Type
9.1.1 Asia Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
9.1.2 Asia Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
9.2 Asia Short-acting Recombinant Human Erythropoietin Market Size by Application
9.2.1 Asia Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
9.2.2 Asia Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
9.3 Asia Short-acting Recombinant Human Erythropoietin Sales by Region
9.3.1 Asia Short-acting Recombinant Human Erythropoietin Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Short-acting Recombinant Human Erythropoietin Revenue by Region (2018-2029)
9.3.3 Asia Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Market Size by Type
10.1.1 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Market Size by Application
10.2.1 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Country
10.3.1 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Amgen Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Overview
11.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Johnson & Johnson Recent Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Overview
11.3.3 Roche Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Roche Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Roche Recent Developments
11.4 Kyowa Kirin
11.4.1 Kyowa Kirin Company Information
11.4.2 Kyowa Kirin Overview
11.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Kyowa Kirin Recent Developments
11.5 LG Chem
11.5.1 LG Chem Company Information
11.5.2 LG Chem Overview
11.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 LG Chem Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 LG Chem Recent Developments
11.6 Daewoong Pharmaceutical
11.6.1 Daewoong Pharmaceutical Company Information
11.6.2 Daewoong Pharmaceutical Overview
11.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Daewoong Pharmaceutical Recent Developments
11.7 Wockhardt
11.7.1 Wockhardt Company Information
11.7.2 Wockhardt Overview
11.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Wockhardt Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Wockhardt Recent Developments
11.8 CJ Healthcare
11.8.1 CJ Healthcare Company Information
11.8.2 CJ Healthcare Overview
11.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 CJ Healthcare Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 CJ Healthcare Recent Developments
11.9 3SBio
11.9.1 3SBio Company Information
11.9.2 3SBio Overview
11.9.3 3SBio Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 3SBio Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 3SBio Recent Developments
11.10 Kexing Biopharm
11.10.1 Kexing Biopharm Company Information
11.10.2 Kexing Biopharm Overview
11.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Kexing Biopharm Recent Developments
11.11 Harbin Pharmaceutical Group
11.11.1 Harbin Pharmaceutical Group Company Information
11.11.2 Harbin Pharmaceutical Group Overview
11.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Harbin Pharmaceutical Group Recent Developments
11.12 Beijing Four Rings Bio-Pharmaceutical
11.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
11.12.2 Beijing Four Rings Bio-Pharmaceutical Overview
11.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Short-acting Recombinant Human Erythropoietin Industry Chain Analysis
12.2 Short-acting Recombinant Human Erythropoietin Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Short-acting Recombinant Human Erythropoietin Production Mode & Process
12.4 Short-acting Recombinant Human Erythropoietin Sales and Marketing
12.4.1 Short-acting Recombinant Human Erythropoietin Sales Channels
12.4.2 Short-acting Recombinant Human Erythropoietin Distributors
12.5 Short-acting Recombinant Human Erythropoietin Customers
13 Market Dynamics
13.1 Short-acting Recombinant Human Erythropoietin Industry Trends
13.2 Short-acting Recombinant Human Erythropoietin Market Drivers
13.3 Short-acting Recombinant Human Erythropoietin Market Challenges
13.4 Short-acting Recombinant Human Erythropoietin Market Restraints
14 Key Findings in The Global Short-acting Recombinant Human Erythropoietin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Short-acting Recombinant Human Erythropoietin Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Epoetin-alfa
Table 3. Major Manufacturers of Epoetin-beta
Table 4. Major Manufacturers of Darbepoetin-alfa
Table 5. Major Manufacturers of Others
Table 6. Global Short-acting Recombinant Human Erythropoietin Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Short-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Short-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Short-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2024)
Table 11. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2024-2029)
Table 12. Global Short-acting Recombinant Human Erythropoietin Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 14. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 15. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2024)
Table 16. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Region (2024-2029)
Table 17. Global Short-acting Recombinant Human Erythropoietin Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Short-acting Recombinant Human Erythropoietin Sales Share by Manufacturers (2018-2024)
Table 19. Global Short-acting Recombinant Human Erythropoietin Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Short-acting Recombinant Human Erythropoietin, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Short-acting Recombinant Human Erythropoietin Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Short-acting Recombinant Human Erythropoietin Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Short-acting Recombinant Human Erythropoietin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting Recombinant Human Erythropoietin as of 2022)
Table 25. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Product Offered and Application
Table 27. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 30. Global Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 31. Global Short-acting Recombinant Human Erythropoietin Sales Share by Type (2018-2024)
Table 32. Global Short-acting Recombinant Human Erythropoietin Sales Share by Type (2024-2029)
Table 33. Global Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Short-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Type (2018-2024)
Table 36. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Type (2024-2029)
Table 37. Short-acting Recombinant Human Erythropoietin Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Short-acting Recombinant Human Erythropoietin Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 40. Global Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 41. Global Short-acting Recombinant Human Erythropoietin Sales Share by Application (2018-2024)
Table 42. Global Short-acting Recombinant Human Erythropoietin Sales Share by Application (2024-2029)
Table 43. Global Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Short-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Application (2018-2024)
Table 46. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Application (2024-2029)
Table 47. Short-acting Recombinant Human Erythropoietin Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Short-acting Recombinant Human Erythropoietin Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Short-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Short-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 62. Europe Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 63. Europe Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 64. Europe Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Short-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 67. Europe Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 68. Europe Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Short-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Short-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Short-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 74. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 75. China Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 76. China Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 77. China Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Short-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 80. China Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 81. China Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Short-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 84. Asia Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 85. Asia Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Short-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 88. Asia Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 89. Asia Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Short-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Short-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Short-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Short-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 95. Asia Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 109. Amgen Company Information
Table 110. Amgen Description and Major Businesses
Table 111. Amgen Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Amgen Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Amgen Recent Developments
Table 114. Johnson & Johnson Company Information
Table 115. Johnson & Johnson Description and Major Businesses
Table 116. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Johnson & Johnson Recent Developments
Table 119. Roche Company Information
Table 120. Roche Description and Major Businesses
Table 121. Roche Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Roche Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Roche Recent Developments
Table 124. Kyowa Kirin Company Information
Table 125. Kyowa Kirin Description and Major Businesses
Table 126. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Kyowa Kirin Recent Developments
Table 129. LG Chem Company Information
Table 130. LG Chem Description and Major Businesses
Table 131. LG Chem Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. LG Chem Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. LG Chem Recent Developments
Table 134. Daewoong Pharmaceutical Company Information
Table 135. Daewoong Pharmaceutical Description and Major Businesses
Table 136. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Daewoong Pharmaceutical Recent Developments
Table 139. Wockhardt Company Information
Table 140. Wockhardt Description and Major Businesses
Table 141. Wockhardt Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Wockhardt Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Wockhardt Recent Developments
Table 144. CJ Healthcare Company Information
Table 145. CJ Healthcare Description and Major Businesses
Table 146. CJ Healthcare Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. CJ Healthcare Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. CJ Healthcare Recent Developments
Table 149. 3SBio Company Information
Table 150. 3SBio Description and Major Businesses
Table 151. 3SBio Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. 3SBio Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. 3SBio Recent Developments
Table 154. Kexing Biopharm Company Information
Table 155. Kexing Biopharm Description and Major Businesses
Table 156. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Kexing Biopharm Recent Developments
Table 159. Harbin Pharmaceutical Group Company Information
Table 160. Harbin Pharmaceutical Group Description and Major Businesses
Table 161. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 162. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 163. Harbin Pharmaceutical Group Recent Developments
Table 164. Beijing Four Rings Bio-Pharmaceutical Company Information
Table 165. Beijing Four Rings Bio-Pharmaceutical Description and Major Businesses
Table 166. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 167. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 168. Beijing Four Rings Bio-Pharmaceutical Recent Developments
Table 169. Key Raw Materials Lists
Table 170. Raw Materials Key Suppliers Lists
Table 171. Short-acting Recombinant Human Erythropoietin Distributors List
Table 172. Short-acting Recombinant Human Erythropoietin Customers List
Table 173. Short-acting Recombinant Human Erythropoietin Market Trends
Table 174. Short-acting Recombinant Human Erythropoietin Market Drivers
Table 175. Short-acting Recombinant Human Erythropoietin Market Challenges
Table 176. Short-acting Recombinant Human Erythropoietin Market Restraints
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Short-acting Recombinant Human Erythropoietin Product Picture
Figure 2. Global Short-acting Recombinant Human Erythropoietin Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Short-acting Recombinant Human Erythropoietin Market Share by Type in 2022 & 2029
Figure 4. Epoetin-alfa Product Picture
Figure 5. Epoetin-beta Product Picture
Figure 6. Darbepoetin-alfa Product Picture
Figure 7. Others Product Picture
Figure 8. Global Short-acting Recombinant Human Erythropoietin Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Short-acting Recombinant Human Erythropoietin Market Share by Application in 2022 & 2029
Figure 10. Anemia
Figure 11. Kidney Disorders
Figure 12. Others
Figure 13. Short-acting Recombinant Human Erythropoietin Report Years Considered
Figure 14. Global Short-acting Recombinant Human Erythropoietin Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Short-acting Recombinant Human Erythropoietin Revenue 2018-2029 (US$ Million)
Figure 16. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2029)
Figure 18. Global Short-acting Recombinant Human Erythropoietin Sales 2018-2029 ((K Units)
Figure 19. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Short-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Short-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Short-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Short-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Short-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 25. China Short-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Short-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Short-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Short-acting Recombinant Human Erythropoietin Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Short-acting Recombinant Human Erythropoietin in the World: Market Share by Short-acting Recombinant Human Erythropoietin Revenue in 2022
Figure 32. Global Short-acting Recombinant Human Erythropoietin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 34. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 35. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 36. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Short-acting Recombinant Human Erythropoietin Revenue Share by Country (2018-2029)
Figure 42. US & Canada Short-acting Recombinant Human Erythropoietin Sales Share by Country (2018-2029)
Figure 43. U.S. Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 46. Europe Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 47. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 48. Europe Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 49. Europe Short-acting Recombinant Human Erythropoietin Revenue Share by Country (2018-2029)
Figure 50. Europe Short-acting Recombinant Human Erythropoietin Sales Share by Country (2018-2029)
Figure 51. Germany Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 52. France Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 56. China Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 57. China Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 58. China Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 59. China Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 60. Asia Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 61. Asia Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 62. Asia Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 63. Asia Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 64. Asia Short-acting Recombinant Human Erythropoietin Revenue Share by Region (2018-2029)
Figure 65. Asia Short-acting Recombinant Human Erythropoietin Sales Share by Region (2018-2029)
Figure 66. Japan Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 70. India Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Short-acting Recombinant Human Erythropoietin Sales Share by Country (2018-2029)
Figure 77. Brazil Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Short-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 82. Short-acting Recombinant Human Erythropoietin Value Chain
Figure 83. Short-acting Recombinant Human Erythropoietin Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed